Page results
-
RESPOND – Information for healthcare professionals and services working with asylum seekers
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
Nine Covid-19 research studies are already taking place at UCLH and the Trust is processing more than 30 study proposals as research efforts around the virus and pandemic are ramped up.
-
Read more about a UCLH patient saved by special 'before midnight' transfusions.
-
Read more about the NHS Staff Survey 2024 - we’re the top acute trust to work at for third year running!
-
UCLH is continuing to scale up the number of services that offer Advice & Guidance, as well as identifying various improvements within the existing Advice & Guidance service. Over the last few months, UCLH has introduced 5 new specialties to the service, with additional specialties due to go live shortly.
-
UCLH will play a vital role in a new respiratory virus study.
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
Holistic Needs Assessment (HNA): Information for people affected by cancer and blood conditions patient information leaflet
File results
-
FOI/2022/0686 - Breast cancer patients
-
FOI/2022/0672 - Data Centre
-
FOI/2022/0674 - Maternity locum staffing
-
FOI/2022/0675 - Drug treatment for Paediatric patients (ages 0-16)
-
FOI/2022/0677 - Documents relating to the lift being out of order (RLHIM Lift 2 by reception)
-
FOI/2022/0679 - Theatre management, AA's and ODPs
-
FOI/2022/0681 - Deep brain stimulation procedure
-
FOI/2022/0704 - Elective operations cancelled for non-clinical reasons
-
FOI/2022/0707 - Current endoscopy maintenance supplier and the contract expiry date
-
FOI/2022/0705 - Head/ neck and urothelial cancer treatment